Edition:
United Kingdom

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

4.73USD
25 Apr 2018
Change (% chg)

$-0.04 (-0.84%)
Prev Close
$4.77
Open
$4.80
Day's High
$4.80
Day's Low
$4.65
Volume
3,243
Avg. Vol
19,909
52-wk High
$7.73
52-wk Low
$4.42

Chart for

About

Therapix Biosciences Ltd, formerly Nasvax Ltd, is an Israel-based company active in the pharmaceutical sector. The Company develops improved vaccines and immunotherapeutics. Its products include Anti-CD3 oral immunotherapy, directed toward the treatment of inflammatory and autoimmune diseases; Group-common Pneumococcal Vaccine,... (more)
No analyst recommendations are available for .

Overall

Beta: -2.06
Market Cap(Mil.): ₪67.93
Shares Outstanding(Mil.): 138.36
Dividend: --
Yield (%): --

Financials

  TRPX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.19 -- --
ROI: -210.69 14.84 14.38
ROE: -209.27 16.34 16.07

BRIEF-Therapix Biosciences - Co Terminated Research & License Agreement Between Co, Yissum Research Development Co

* THERAPIX BIOSCIENCES - ON MARCH 18, 2018 CO TERMINATED RESEARCH & LICENSE AGREEMENT BETWEEN CO, YISSUM RESEARCH DEVELOPMENT CO, DATED MARCH 30, 2017 Source text: (https://bit.ly/2F372wh) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

20 Apr 2018

BRIEF-Therapix Biosciences Announces Topline Results Of Phase IIA Study At Yale University For Tourette Syndrome Program

* THERAPIX BIOSCIENCES ANNOUNCES TOPLINE RESULTS OF PHASE IIA STUDY AT YALE UNIVERSITY FOR TOURETTE SYNDROME PROGRAM Source text for Eikon: Further company coverage:

09 Apr 2018

BRIEF-Therapix Biosciences Says U.S. FDA Cleared IND For THX-110 In Treatment Of Chronic Low Back Pain

* THERAPIX BIOSCIENCES - U.S. FDA CLEARED IND FOR THX-110 IN TREATMENT OF CHRONIC LOW BACK PAIN

20 Mar 2018

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018

07 Feb 2018

BRIEF-Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary

* THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018

09 Jan 2018

BRIEF-Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement

* THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING

26 Dec 2017

Therapix expects to have results of Tourette's drug trial by end of first quarter

TEL AVIV Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

04 Dec 2017

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.

04 Dec 2017

BRIEF-Therapix Biosciences plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids

* Therapix Biosciences Ltd plans preclinical study to evaluate opioid-sparing effects of two innovative synthetic cannabinoids Source text for Eikon: Further company coverage:

10 Nov 2017

BRIEF-Therapix Biosciences Q3 loss per share $0.30

* Therapix Biosciences reports third quarter 2017 financial results and provides business update

09 Nov 2017

Earnings vs. Estimates